Bp Plc bought a new stake in shares of Henry Schein Inc. (NASDAQ:HSIC) during the second quarter, Holdings Channel reports. The firm bought 10,000 shares of the company’s stock, valued at approximately $1,768,000.
Several other hedge funds have also recently modified their holdings of HSIC. Quadrant Capital Group LLC raised its stake in shares of Henry Schein by 0.4% in the second quarter. Quadrant Capital Group LLC now owns 742 shares of the company’s stock valued at $128,000 after buying an additional 3 shares during the last quarter. Essex Financial Services Inc. purchased a new stake in shares of Henry Schein during the second quarter valued at about $203,000. Wagner Bowman Management Corp purchased a new stake in shares of Henry Schein during the second quarter valued at about $231,000. Berkshire Asset Management LLC PA purchased a new stake in shares of Henry Schein during the second quarter valued at about $246,000. Finally, Eqis Capital Management Inc. raised its stake in shares of Henry Schein by 23.4% in the second quarter. Eqis Capital Management Inc. now owns 1,639 shares of the company’s stock valued at $290,000 after buying an additional 311 shares during the last quarter. Hedge funds and other institutional investors own 92.03% of the company’s stock.
Henry Schein Inc. (NASDAQ:HSIC) traded down 0.10% during trading on Monday, hitting $153.21. The stock had a trading volume of 599,709 shares. Henry Schein Inc. has a 52-week low of $142.64 and a 52-week high of $183.00. The firm has a market cap of $12.53 billion, a P/E ratio of 25.95 and a beta of 1.05. The company has a 50-day moving average of $162.17 and a 200 day moving average of $170.06.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Thursday, August 4th. The company reported $1.64 EPS for the quarter, topping the Zacks’ consensus estimate of $1.63 by $0.01. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The company had revenue of $2.87 billion for the quarter, compared to analysts’ expectations of $2.85 billion. During the same period last year, the firm earned $1.46 EPS. Henry Schein’s revenue for the quarter was up 9.3% compared to the same quarter last year. On average, equities research analysts predict that Henry Schein Inc. will post $6.57 earnings per share for the current fiscal year.
A number of research firms recently issued reports on HSIC. Zacks Investment Research lowered Henry Schein from a “hold” rating to a “sell” rating in a research note on Monday. Robert W. Baird lowered Henry Schein from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $176.00 to $164.00 in a research note on Friday. Goldman Sachs Group Inc. upgraded Henry Schein from a “neutral” rating to a “buy” rating and set a $185.00 price objective on the stock in a research note on Tuesday, October 11th. Finally, Bank of America Corp. began coverage on Henry Schein in a research note on Monday, September 12th. They set a “buy” rating and a $185.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $159.50.
In other Henry Schein news, Director Paul Brons sold 3,381 shares of the firm’s stock in a transaction dated Monday, August 29th. The stock was sold at an average price of $164.03, for a total transaction of $554,585.43. Following the sale, the director now directly owns 13,715 shares of the company’s stock, valued at $2,249,671.45. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.27% of the stock is owned by corporate insiders.
About Henry Schein
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.